Close Menu

Cracking the Market

Philadelphia-based Mylan and India-based Biocon are teaming up to develop generic biotech drugs. "It makes sense that Mylan, which is an expert in making generic copies of traditional drugs, would partner with an outside firm that focuses on biotech. By the same token, cracking the market for generic biotechs in the developed world might also be tricky - so it makes sense that an Indian firm might want a U.S. partner," says the Wall Street Journal Health Blog.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.